Clinical application of a bioactive nano-hydroxyapatite/polyamide 66 interbody fusion cage / 中国组织工程研究

ABSTRACT

BACKGROUND:There are various commonly used interbody fusion methods, such as autologous bone, al ograft bone and titanium-based posterior lumbar interbody fusion, and each method has its own advantages and disadvantages. OBJECTIVE:To observe the clinical efficacy of a bioactive nano-hydroxyapatite/polyamide 66 fusion cage in posterior lumbar interbody fusion for the treatment of lumbar disease. METHODS:A retrospective case analysis was conducted on 16 cases treated with posterior lumbar interbody fusion at the Department of Orthopedic, the First Affiliated Hospital of Gannan Medical University from July 2010 to December 2011, and al the patients were implanted with nano-hydroxyapatite/polyamide 66 biological activity fusion cage. RESULTS AND CONCLUSION:Al the patients were fol owed-up for 10-24 months, and the lumbar pain was significant improved, the lumbar visual analogue score, lumbar Japanese Orthopaedic Association score and Oswestry disability index score were significantly improved during the final fol ow-up period (Pfusion without nano-hydroxyapatite/polyamide 66 fusion cage displacement or subsidence. The results indicate that nano-hydroxyapatite/polyamide 66 fusion cage for the treatment of posterior lumbar interbody fusion can reconstruct the lumbar stability and provide immediate stability after implantation, and has good biological activity.